Quick Answer
Bionano Genomics, Inc. reported Total Assets of $73.58 million for the year ending 2025.
- Bionano Genomics, Inc. showed a decrease of -4.0% in Total Assets from 2024 to 2025.
- This data is from Bionano Genomics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $30.67 million | Q1 2019: $29.55 million | Q2 2019: $25.21 million | Q3 2019: $19.21 million | Q1 2020: $19.10 million | Q2 2020: $27.20 million | Q3 2020: $41.40 million | Q1 2021: $384.86 million | Q2 2021: $356.81 million | Q3 2021: $359.66 million | Q1 2022: $348.21 million | Q2 2022: $321.55 million | Q3 2022: $323.70 million | Q1 2023: $292.15 million | Q2 2023: $271.38 million | Q3 2023: $181.90 million | Q1 2024: $158.00 million | Q2 2024: $129.36 million | Q3 2024: $87.36 million | Q1 2025: $78.41 million | Q2 2025: $76.01 million | Q3 2025: $79.06 million.
- Over the full 9 years of available data (2017 to 2025), Bionano Genomics, Inc.'s Total Assets has grown by 625.3%.
- Historical annual values: Fiscal year 2025: $73.58 million | Fiscal year 2024: $76.67 million | Fiscal year 2023: $214.40 million | Fiscal year 2022: $307.50 million | Fiscal year 2021: $377.10 million | Fiscal year 2020: $60.45 million | Fiscal year 2019: $30.21 million | Fiscal year 2018: $24.80 million | Fiscal year 2017: $10.15 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: